Gene therapy for skin cancer in recessive dystrophic epidermolysis bullosa
Part of Cancer clinical trials.
This trial tests a gene therapy called BVEC to see if it can prevent squamous cell carcinoma (a type of skin cancer) from coming back in people with a severe form of epidermolysis bullosa (fragile skin). It is for adults who have had a confirmed SCC and are willing to use the gene therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with generalized recessive dystrophic epidermolysis bullosa (RDEB) due to a COL7A1 gene mutation
- You have a biopsy-confirmed squamous cell carcinoma (a type of skin cancer)
- You are 18 years or older
- You can travel to the study site for visits
- You are willing to use the gene therapy (BVEC) and an effective birth control method if needed
- You do not have metastatic SCC (cancer that has spread) or are currently receiving systemic treatment for SCC
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients who have already received a gene therapy treatment called prademagene zamikeracel for a severe skin condition called recessive dystrophic epidermolysis bullosa (RDEB). The goal is to track long-term safety and health outcomes after treatment.
This trial tests a drug called efgartigimod (VYVGART) to see if it can lower harmful antibodies in people with certain blistering skin diseases—dystrophic epidermolysis bullosa (DEB) and epidermolysis bullosa acquisita (EBA). If you have these antibodies, this treatment might help reduce blistering.
This trial tests if intravenous immunoglobulin (IV IgG) can help people with a form of epidermolysis bullosa who have antibodies against collagen VII. It may reduce blistering and improve wound healing.
This study looks at the medical features and needs of people who have recessive dystrophic epidermolysis bullosa (RDEB). It may help doctors better understand the condition and plan better care.
This study looks at long-term outcomes for people with recessive dystrophic epidermolysis bullosa (RDEB) who were previously treated with EB-101. It may help doctors understand how the treatment affects patients over time.
This trial tests a new skin graft made with your own cells that have been genetically modified to produce a missing protein (collagen 7). It's for people with RDEB, a severe blistering condition, and aims to see if the graft can heal wounds safely.
Hear when a new Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.